Clinical Trial Update: Triplet Combination First Line Treatment in Non Small Cell Lung Cancer (NSCLC) [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating a triplet drug combination as first-line therapy for metastatic non-squamous non-small cell lung cancer; the study has completed and re…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Snippet

Sponsor: CanBas Co. Ltd. | Conditions: Metastatic Non-squamous Non Small Cell Lung Cancer | Phase 2 | Status: COMPLETED | Results posted: 2017-05-24